PR-TAD CAPSULES 10MG - 60CT
PR-Tad (Tadalafil) is a synthetic small-molecule phosphodiesterase type 5 (PDE5) inhibitor. Preclinical studies in cell cultures and animal models indicate that Tadalafil selectively inhibits PDE5, leading to increased cyclic GMP (cGMP) levels, smooth muscle relaxation, and enhanced vasodilation in vascular tissues.[1][2]
Key Research Areas
- Vasodilation & Vascular Function – In rodent models of vascular dysfunction and pulmonary hypertension, Tadalafil has been shown to relax vascular smooth muscle, improve endothelial function, and enhance blood flow through cGMP-mediated pathways.[3][4]
- Pulmonary & Cardiovascular Protection – Preclinical investigations demonstrate Tadalafil reduces pulmonary arterial pressure, attenuates right ventricular hypertrophy, and protects against hypoxia-induced vascular remodeling in models of pulmonary arterial hypertension.[5][6]
- Tissue Perfusion & Anti-Platelet Effects – Animal studies suggest Tadalafil improves tissue perfusion, inhibits platelet aggregation, and supports endothelial integrity in models of ischemia-reperfusion and thrombosis.[7][8]
Product Specifications
| Form |
Oral capsules (research use only) |
| CAS Number |
171596-29-5 |
| Molecular Formula |
C22H19N3O4 |
| Molar Mass |
389.40 g/mol |
| Synonyms |
Tadalafil, Tad |
| Purity |
≥99% (HPLC) |
| Storage |
Room temp, protect from light and moisture |
| Other Details |
Excipients: Research-grade fillers/capsule material |
References
- 1. Francis SH, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010. PubMed
- 2. Corbin JD, et al. The molecular mechanisms of cGMP signaling in vascular smooth muscle. Trends Pharmacol Sci. 2002. PubMed
- 3. Galiè N, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009. (Preclinical context)
- 4. Porst H, et al. Tadalafil once daily in the treatment of erectile dysfunction: efficacy and safety. Eur Urol. 2006. (Vascular data)
- 5. McLaughlin VV, et al. Pulmonary arterial hypertension. Circulation. 2009. PubMed
- 6. Archer SL, et al. Phosphodiesterase type 5 inhibitors in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009. PubMed
- 7. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004. PubMed
- 8. Jackson G, et al. Cardiovascular effects of tadalafil. Am J Cardiol. 2003. PubMed
All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.
